The AJMC® Chronic Kidney Disease compendium is a comprehensive resource for clinical news and expert insights on the condition and treatment of loss of kidney function.
March 28th 2024
The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
CDC, ASN Address COVID-19 Challenges in Dialysis Setting
March 30th 2020In a response to the coronavirus disease 2019 (COVID-19) pandemic, the American Society of Nephrology (ASN) has hosted series of webinars outlining CDC recommendations and policy changes for challenges in the dialysis setting.
Read More
Dr Cynthia Delgado: Research Needed on Disability Experiences of Patients With CKD Over Time
February 28th 2020Although many investigators have pushed the envelope in researching how patients with chronic kidney disease (CKD) experience disabilities, there is still a need for more knowledge on how those disabilities evolve over time, according to Cynthia Delgado, MD, associate professor of medicine at the San Francisco Veterans Affairs Medical Center and University of California San Francisco Medical Center.
Watch
Dr Cynthia Delgado Outlines How Frailty Affects Outcomes in Patients Receiving Hemodialysis
February 20th 2020Frailty significantly raises the risk of developing disabilities as a result of hemodialysis, so even patients who are intermediately frail should be monitored, said Cynthia Delgado, MD, associate professor of medicine at the San Francisco Veterans Affairs Medical Center and University of California San Francisco Medical Center.
Watch
Dr Joseph Vassalotti Describes Ways to Empower Primary Care Clinicians to Treat Kidney Disease
February 13th 2020Educating primary care clinicians on how to manage chronic kidney disease in the primary care setting can help avoid referrals for nephrology consults that aren’t needed, said Joseph Vassalotti, MD, clinical professor at Icahn School of Medicine at Mount Sinai and chief medical officer of the National Kidney Foundation.
Watch
PAPER OF THE WEEK: When Patients With Kidney Failure Still Don't Take Medication
February 8th 2020The article identifies issues such as poor socioeconomic background and lack of family and social support as factors in poor medication adherence, which today are recognized as social determinants of health
Read More
Medicare Advantage Proposal Includes Steps to Implement Kidney Care Plan
February 7th 2020The plan represents the latest element of the Trump administration’s comprehensive approach to renal care, which seeks to keep patients from advancing to dialysis. For those who do, the plan promotes transplants and home dialysis options.
Read More
Dr Joseph Vassalotti Explains How CKDintercept's Components Can Improve Kidney Care
February 5th 2020CKDintercept, the primary care initiative of the National Kidney Foundation, involves multiple strategies aimed at improving the quality of kidney care, explained Joseph Vassalotti, MD, clinical professor at Icahn School of Medicine at Mount Sinai and chief medical officer of the National Kidney Foundation.
Watch
Dr Cynthia Delgado Explains How Patients With Disabilities Experience Kidney Care Differently
February 2nd 2020Physical disabilities may make it difficult for patients with chronic kidney disease to follow provider recommendations and achieve a good therapeutic alliance, which can lead to increased burden of illness, according to Cynthia Delgado, MD, associate professor of medicine at the San Francisco Veterans Affairs Medical Center and University of California San Francisco Medical Center.
Watch
Physicians, Patient Discuss Intentional Nonadherence in Hypertension Therapy
November 10th 2019What should providers do about intentional nonadherence, and what strategies should they try to get their patients to take their hypertension medicine? At a session at the American Society of Nephrology (ASN)’s Kidney Week 2019, physicians discussed direct observation therapy (DOT), drug monitoring, case studies, and other published work about patients who don’t take their medications. Then they heard from a directly from a patient who shared why she stopped taking her medication and the scary consequence that developed as a result.
Read More
CKD Quality Improvement Intervention With PCMH Integration: Health Plan Results
A scalable chronic kidney disease (CKD) quality improvement intervention demonstrated feasibility, decreased hospitalization, and reduced costs. These preliminary results support innovation in CKD by commercial health plans.
Read More
Dr Danielle Kirkman Explains How Exercise Testing in Patients With CKD Can Improve Care
November 8th 2019Because exercise capacity is known to be linked with several key outcome measures in patients with chronic kidney disease (CKD), routine exercise testing can help clinicians prescribe individualized exercise interventions, said Danielle Kirkman, PhD, assistant professor at Virginia Commonwealth University.
Watch
FDA Approves Canagliflozin to Prevent Kidney Failure, Hospitalization for Heart Failure
October 1st 2019The new indication is based on results of the CREDENCE trial, which found that canagliflozin reduced the risk of renal failure or death by 30% in those that had both type 2 diabetes and diabetic kidney disease.
Read More
FDA Grants Fast Track Designation for Dapagliflozin to Prevent Kidney Failure
August 27th 2019Dapagliflozin’s fast track designation follows findings from last year’s DECLARE-TIMI trial, a cardiovascular outcomes trial that showed the drug’s significant impact on delaying the loss of kidney function and reducing hospitalization risk for heart failure.
Read More
AstraZeneca's Khan Discusses Dapagliflozin and Cardiovascular, Renal Outcomes in Diabetes Care
June 29th 2019A discussion with Naeem Khan, MD, vice president of US cardiovascular and metabolic diseases at AstraZeneca, on lessons from the wave of cardiovascular outcomes trials, the new focus on renal outcomes, and what’s next for SGLT2 inhibitors.
Read More
From the Editor-in-Chief: Evolving Role of T2D Therapy, From Secondary to Primary Prevention
June 28th 2019Evidence that newer type 2 diabetes therapies offer cardiovasular and renal benefits offer opportunities for greater collaboration among specialists and more value for patients. Payers must take notice.
Read More
More CV, Renal Outcomes at ADA: CREDENCE, CARMELINA, CAROLINA
June 12th 2019The final morning session of the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California, featured more cardiovascular and renal results from recent trials involving type 2 diabetes drugs.
Read More
Highlighting Links Between Kidney, CV Disease in Diabetes
June 11th 2019The connections among diabetes, cardiovascular (CV) disease, and kidney failure have been a theme of the 79th Scientific Sessions of the American Diabetes Association, which featured a joint session with the American Society of Nephrology.
Read More
CREDENCE Results for Canagliflozin to Be Presented This Weekend in Australia
April 11th 2019The findings represent the first in a new wave of renal outcomes trials in the sodium glucose co-transporter 2 (SGLT2) inhibitor class, a game-changing group of type 2 diabetes drugs with many benefits beyond lowering blood glucose.
Read More
5 Takeaways From the 2019 American College of Cardiology Meeting
March 22nd 2019For SGLT2 inhibitors and a fish oil capsule, there was plenty of good news; for aspirin, not so much. A recap of the American College of Cardiology's 68th Annual Scientific Session, held March 16-18, 2019, in New Orleans, Louisiana.
Read More
Clinical Outcomes and Healthcare Use Associated With Optimal ESRD Starts
Optimal end-stage renal disease (ESRD) starts were associated with lower 12-month morbidity, mortality, and inpatient and outpatient utilization in an integrated healthcare delivery system.
Read More
Physician and Patient Tools to Improve Chronic Kidney Disease Care
Decision support tools, disease registries, and patient engagement materials can improve population-based chronic kidney disease care.
Read More